06/01/2025
Happy New Year from Digistain!
As we step into 2025, we’re reflecting on the incredible progress we made in 2024 and sharing a glimpse of the exciting endeavours ahead.
Innovative Research
This year began with a major milestone: our landmark clinical study was published in Breast Cancer Research and Treatment, validating Digistain as a highly accurate predictor of risk stratification for HR+, HER2- breast cancer patients. An achievement we’re incredibly proud of, with the publication landing in the 97th percentile for readership that month.
https://lnkd.in/dXqCrwnC
We also presented 2 abstracts at the San Antonio Breast Cancer Symposium 2024, including preliminary data from our ongoing head-to-head, multi-centre study assessing Digistain’s predictive accuracy for metastasis-free survival with Oncotype DX. These early results demonstrated that Digistain offers equivalent predictive accuracy to Oncotype DX, underscoring its potential clinical utility.
Global Reach and Adoption
Through strategic efforts, Digistain is now benefiting patients across four continents, with successful endeavours in countries such as India, Malaysia, Thailand, Indonesia, Ecuador, the Philippines, South Africa, and the UK.
This was made possible through forging key partnerships, including collaborations with Deloitte to accelerate Digistain’s adoption across Europe and exclusive agreements with hospitals like Max Healthcare in India and SOLCA in Ecuador. Together, we’re striving to deliver cheaper, faster, more accessible diagnostic solutions to patients worldwide.
Bridging Diagnostic Inequality
Our mission to provide affordable, timely diagnostics and close the gap in diagnostic inequality reached new heights in 2024. Securing reimbursement with major healthcare insurers like Bupa, WPA, and Healix, marking a major step forward in making our technology more accessible to those who need it most.
Looking Ahead to 2025
We’re excited to build on this momentum and expand our research efforts in the year ahead. In 2025, we look forward to publishing our full cost-effectiveness analysis for UK patients, evaluating Digistain’s impact on the healthcare system, alongside the final results from our multi-centre study comparing it to Oncotype DX. Whilst also focusing on building even more partnerships and collaborations to help broaden the reach of Digistain and enhance breast cancer care globally.
Finally, we’re thrilled to announce that we’ve been approved for a national clinical trial to explore the potential of Digistain for multiple solid tumours. We’re excited to embark on this next phase of research, with the hope of expanding our impact and helping patients across a range of cancer types.
We couldn’t have achieved this without our extraordinary team, partners, and supporters. Thank you for being part of our journey. Here’s to another year of innovation, growth, and improving patient outcomes for all.
Wishing you all a successful and prosperous 2025!
